Preliminary Experience with the GORE^® EXCLUDER^® Iliac Branch Endoprosthesis for Common Iliac Aneurysm Endovascular Treatment

详细信息    查看全文

• 作者：Antoine Millon¹ ; ^{antoine.millon@chu-lyon.fr" class="auth_mail" title="E-mail the corresponding author} ; Nellie Della Schiava¹ ; Matthieu Arsicot¹ ; Alberic De Lambert² ; Patrick Feugier¹ ; Jean Luc Magne² ; Patrick Lermusiaux¹
• 刊名：Annals of Vascular Surgery
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：33
• 期：Complete
• 页码：11-17
• 全文大小：867 K

文摘

The aim of this study is to assess the safety and the short-term results of endovascular treatment of common iliac artery (CIA) aneurysms using the new GORE EXCLUDER iliac branch endoprosthesis (IBE) device.

Methods

The study is a retrospective with prospective follow-up nonrandomized, single-arm evaluation. Patients with a CIA aneurysm (diameter >30 mm) extending to the iliac bifurcation underwent endovascular treatment with the Gore IBE. Anatomic and procedural data were collected. Computed tomography angiography (CTA) was performed within the 30 days after the procedure and every 6 month. Thirty-day and at least 6-months outcomes were investigated.

Results

From February 2014 to December 2014, 10 male patients with aneurysmal CIA (mean age 75 years old) underwent consecutive endovascular treatment with the Gore IBE. The CIA aneurysm (mean diameter 43.2 mm, range 32–49) treated with the Gore IBE was associated with an abdominal aortic aneurysm (AAA) in 5 patients. One patient had a previous AAA open repair. CIA aneurysm was bilateral in 5 patients. Preliminary procedure of internal iliac artery embolization was performed in 3 patients. Technical success rate of the Gore IBE implantation was 100% with a median fluoroscopy time of 35 min (range 12–64, ±16) and median contrast load of 150 mL (range 100–250, ±45). No perioperative complications were observed. Median length of stay was 4 days (range 3–7, ±2). One aortic type Ia endoleak was observed on the postoperative CT scan requiring an aortic extension at day 3. Branch patency was observed in all 10 patients at 1 month and 9 patients at 6 month. All CIA aneurysms were excluded without type Ib or type III endoleak.

Conclusions

The technical success and short-term results demonstrate encouraging results and clinical benefits of the new GORE EXCLUDER IBE. A longer follow-up is needed to assess midterm and long-term results.